Targeting nuclear export and Janus Kinase/Signal Transducer and Activator of Transcription (JAK/STAT) signalling in myelofibrosis: A novel combinatorial strategy that impacts intrinsic and microenvironment-related pathways
A two-drug combination targeting disease pathways simultaneously shows promise for myelofibrosis by restoring tumor-suppressing proteins and reducing inflammatory signals in early testing.
This study demonstrates that dual XPO1/JAK2 inhibition using selinexor plus ruxolitinib produces additive anti-proliferative effects on MPN cell lines and suppresses colony formation from MF CD34+ progenitors, while retaining efficacy in a ruxolitinib-resistant MPN cell line by restoring nuclear retention of p53 and disrupting NF-κB and JAK/STAT pathways. Patient PBMC data confirm the combination reduces inflammatory cytokines, suggesting a disease-modifying approach that targets both haematopoietic intrinsic and microenvironmental MF pathways.
What the study was
- Study design
- preclinical_multi_model
- Category
- hematologic_malignancies
- Maturity
- Exploratory
- Journal
- British Journal of Haematology
Why it surfaced
Addresses the pressing clinical problem of ruxolitinib resistance in myelofibrosis; XPO1+JAK2 dual inhibition is mechanistically elegant and clinically rational. Score 7 (N=3, D=1, P=2, E=1) despite preclinical design given high MPN unmet need and imminent translational potential.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.